|
Administration
May be taken with or without food.
|
|
Special Precautions
Patient w/ cardiac co-morbidities, on cardiotoxic chemotherapy and/or w/ concomitant electrolyte abnormalities. May mask progressive ileus and/or gastric distention. Childn. Pregnancy and lactation. Patient Counselling Avoid prolonged exposure to heat (transdermal patch). Monitoring Parameters Monitor for signs of subacute intestinal obstruction; ECG and clinical abnormalities.
|
|
Adverse Reactions
Headache, insomnia, constipation, diarrhoea, elevated hepatic transaminases; QT prolongation; bradycardia, palpitations, sick sinus syndrome, chest pain. Application site reactions (transdermal): Rash, pain, erythema, pruritus, irritation, burn, vesicles, urticaria, discolouration; patch non-adhesion.
|
|
Drug Interactions
Induced metabolism w/ phenobarbital. Risk of serotonin syndrome w/ other serotonergic agents e.g. SSRIs, and serotonin and norepinephrine reuptake inhibitors (SNRIs). Altered clearance w/ CYP enzyme inducers or inhibitors. Concomitant use w/ drugs known to prolong QT interval may result in clinical consequences.
|
|
CIMS Class
|
|
ATC Classification
A04AA02 - granisetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
|
Sign Out
